Neurocrine Biosciences
NBIX
133 hedge funds and large institutions have $1.88B invested in Neurocrine Biosciences in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 11 closing their positions.
80% more capital invested
Capital invested by funds: $1.05B → $1.88B (+$836M)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more call options, than puts
Call options by funds: $20M | Put options by funds: $17.7M
6% more funds holding
Funds holding: 125 → 133 (+8)
5% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$16.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.97M |
| 3 |
FAM
Fred Alger Management
New York
|
+$8.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.22M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.47M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.24M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$4.51M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.06M |
| 5 |
Aviva
London,
United Kingdom
|
-$1.85M |
NBIX Hedge Fund Activity: Q3 2014 in Review
133 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2014, worth a combined $1.88B — up 80% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NBIX positions and 11 closed out — a net gain of 8 holders — while 44 added to existing stakes and 42 trimmed.
The largest buyer was OrbiMed, adding an estimated $16.7M. The largest seller was Franklin Resources, cutting an estimated $5.47M.
- 133 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2014, up from 125 in Q2 2014.
- Funds reported $1.88B of Neurocrine Biosciences stock for Q3 2014, up 80% quarter-over-quarter.
- 19 funds opened new Neurocrine Biosciences positions in Q3 2014 and 11 closed out, a net change of +8 holders.
- The largest Neurocrine Biosciences buyer in Q3 2014 was OrbiMed, an estimated $16.7M added.
- The largest Neurocrine Biosciences seller in Q3 2014 was Franklin Resources, an estimated $5.47M sold.
Based on aggregated 13F filings for Q3 2014.